The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and AT III testing specifically, will become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the AT III testing closer to the patient, creating additional opportunities and challenges for suppliers.This report presents a detailed analysis of the AT III testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5- and 10-year test volume forecasts by country and market segment.The report examines market applications of chromogenic substrates, monoclonal antibodies, immunoassays, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products;... Research Beam Model: Research Beam Product ID: 664121 0 USD New
2016-2020 World Antithrombin III Testing Market: Ambulatory Centers, Commercial Labs, Hospitals, Physician Offices, POC/Point-of-Care Locations--Competitive Landscape, Country Segment Forecasts, Innovative Technologies, Instrumentation Review

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

2016-2020 World Antithrombin III Testing Market: Ambulatory Centers, Commercial Labs, Hospitals, Physician Offices, POC/Point-of-Care Locations--Competitive Landscape, Country Segment Forecasts, Innovative Technologies, Instrumentation Review

 
  • Category : Diagnostic and Biotech
  • Published On : March  2016
  • Pages : 197
 
 

The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and AT III testing specifically, will become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the AT III testing closer to the patient, creating additional opportunities and challenges for suppliers.

This report presents a detailed analysis of the AT III testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5- and 10-year test volume forecasts by country and market segment.

The report examines market applications of chromogenic substrates, monoclonal antibodies, immunoassays, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 197 pages and 8 tables